LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To help diagnose and sometimes to monitor porphyrias
When you have symptoms that suggest a neurologic porphyria (e.g., abdominal pain, tingling or numbness in the hands or feet, muscular weakness and/or alterations in thought or mood) or a cutaneous porphyria (e.g., redness, blistering, or scarring of sun-exposed skin)
A blood sample drawn from a vein in your arm, a random or 24-hour urine sample, and/or a stool sample
If a neurologic porphyria is suspected, the sample should be collected during an acute attack.
Porphyrins are a group of compounds defined by their chemical structure. These compounds are by-products of heme synthesis and are normally present at low concentrations in blood and other body fluids. Porphyrin tests measure porphyrins and their precursors in urine, blood, and/or stool.
Heme is an iron-containing pigment that is a component of hemoglobin and a number of other proteins. It consists of an organic portion (protoporphyrin) bound to an iron atom. The synthesis of heme is a step-by-step process that requires the sequential action of eight different enzymes. If there is a deficiency in one of these enzymes, the process is impeded and intermediate porphyrins such as uroporphyrin, coproporphyrin, and protoporphyrin build up in the body's fluids and tissues. The precursors that accumulate depend on which enzyme is deficient, and they can exert toxic effects.
Porphyrin tests are used to help diagnose and monitor a group of disorders called porphyrias. There are seven types of porphyria, and each one is associated with a different enzyme deficiency. Most porphyrias are inherited, the result of a gene mutation. They may be classified according to the signs and symptoms of the disease as neurological, cutaneous, or both.
The porphyrias that cause neurological symptoms present with acute attacks lasting days or weeks. Signs and symptoms during the attack include abdominal pain, constipation, confusion, hallucinations, and/or seizures. There are four neurologic porphyrias: acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), and the very rare ALA dehydratase deficiency porphyria (ADP). Some cases of VP and HCP may also have skin-related symptoms.
The cutaneous porphyrias are associated with photosensitivity that causes redness, swelling, a burning sensation, blistering, skin thickening, hyperpigmentation, and/or scarring. There are three cutaneous porphyrias: porphyria cutanea tarda (PCT), erythropoietic protoporphyria (EPP), and congenital erythropoietic porphyria (CEP). For more information about each disease, see the article on Porphyria.
To diagnose porphyrias, clinical laboratories measure porphyrins and their precursors in urine, blood, and/or stool. Testing may include measurement of one or more of the following:
Specialized laboratories may offer testing for one or more of the affected enzymes. The most commonly measured enzyme is porphobilinogen deaminase (PBG-D) in red blood cells, which tests for acute intermittent porphyria. A few laboratories offer genetic testing for specific gene mutations that cause one of the porphyrias, but this type of testing is not widely available.
The sample type depends on the porphyrin tests ordered by the healthcare practitioner. It may include one or more of the following:
If a neurologic porphyria is suspected, the sample should be collected during an acute attack.
Porphyrin testing is used to help diagnose and sometimes to monitor porphyrias. These disorders can be classified into two groups based on signs and symptoms: neurologic porphyrias and cutaneous porphyrias. As some porphyrias can have similar symptoms, testing is also used to help determine which type is present. A healthcare practitioner will choose individual tests based on the affected person's signs and symptoms as well as the medical and family history.
Neurologic porphyrias are associated with acute attacks involving the nervous system and/or gastrointestinal tract. They include acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), and ALA dehydratase deficiency porphyria (ADP).
Tests for neurologic porphyrias are given below:
Cutaneous porphyrias produce skin-related symptoms. This type includes porphyria cutanea tarda, (PCT), erythropoietic protoporphyria (EPP) and congenital erythropoietic porphyria (CEP).
Tests for cutaneous porphyrias are given below:
These tests may sometimes be used to monitor the disease in patients who have been diagnosed with a porphyria.
Enzyme testing may be used to confirm the diagnosis of acute intermittent porphyria (by measuring porphobilinogen deaminase in red blood cells). Genetic testing for porphyria is not widely available, but it is another way to establish the diagnosis. Both types of tests may be used to identify family members who have inherited a porphyria, even if they do not have signs and symptoms of the disease.
Porphyrin tests are ordered when an individual has signs and symptoms that a healthcare practitioner suspects are due to a porphyria. Typically, the person will have either neurologic symptoms or skin-related symptoms, but those with VP or HCP may have both.
Acute neurologic porphyrias—tests may be ordered when someone has acute attacks lasting for days to weeks. The attacks may be triggered by a variety of drugs or environmental factors such as dietary changes, stress, and exposure to toxic substances. The attacks may include signs and symptoms, such as:
Cutaneous porphyrias—tests may be ordered when someone has one or more signs and symptoms affecting sun-exposed areas of the skin, such as:
When an individual has been diagnosed with a porphyria, testing may be performed on a regular basis to monitor the condition.
Care must be taken when interpreting porphyrin test results. Results are typically reported as below an established threshold (normal) or, if increased, reported as a specific level.
One or more of the porphyrins and their precursors are usually elevated in each of the porphyrias, and the pattern of elevation (which porphyrin is elevated in which sample) helps determine the diagnosis. For example, urine PBG is significantly increased in people with a neurologic porphyria. However, porphyrins may be increased up to several-fold in a variety of other conditions. In addition, levels may fall to near normal levels between acute attacks of a neurologic porphyria. Interpretation of the patterns can be difficult and should be done by a physician or laboratory scientist with expertise in porphyrias.
If the initial test results are negative, it means that it is unlikely that a person's symptoms are caused by a porphyria. Initial tests that are positive should be confirmed with follow-up testing.
People usually do not need to have all of these tests performed. The following table summarizes the patterns of results that are typical for each type of porphyria:
|Type of Porphyria||Urine ALA and PBG*||Urine porphyrins||Fecal porphyrins||Red Blood Cell Porphyrins|
|Acute intermittent porphyria||Increased||Increased URO*||Normal||Normal|
|Variegate porphyria||Increased||Increased COPRO||Increased PROTO, COPRO||Normal|
|Hereditary coproporphyria||Increased||Increased COPRO||Increased COPRO||Normal|
|ALA dehydratase deficiency||Increased ALA only||Increased COPRO||Increased PROTO|
|Porphyria cutanea tarda||Normal||Increased URO, 7-carboxyl||Increased Isocoproporphyrin||Normal|
|Erythropoietic Protoporphyria||Normal||Normal||Increased PROTO||Increased PROTO|
|Congenital erythropoietic porphyria||Normal||Increased URO, COPRO||Increased COPRO||Increased URO, COPRO|
|PBG = Porphobilinogen; ALA = Aminolevulinic acid; URO = Uroporphyrin; COPRO = Coproporphyrin; PROTO = Protoporphyrin|
|* May be increased only during acute attack|
Table adapted from: "Iron and porphyrin metabolism," Clinical Chemistry: Theory, Analysis and Correlation, courtesy of William E. Schreiber, MD.
If enzyme testing is performed, a low level of the enzyme can help confirm a diagnosis. For example, a decreased level of porphobilinogen deaminase confirms the diagnosis of acute intermittent porphyria.
An abnormal enzyme test or the detection of a gene mutation indicates that a family member has inherited a porphyria. However, enzyme and gene tests cannot determine whether that individual will develop signs and symptoms of the porphyria or, if the person does, how severe they are likely to be. Fortunately, the majority of gene carriers never have an attack.
The diagnosis of a porphyria can be difficult. As a group, these diseases are uncommon or rare, and the signs and symptoms can be seen mimic other, more common diseases.
A variety of drugs, alcohol, and other environmental factors such as diets, stress, and illness, can trigger acute attacks of a neurologic porphyria in those with latent or inactive disease. By the same token, sun exposure can induce skin lesions in people with a cutaneous porphyria. Lifestyle modifications to avoid aggravating factors are the most effective way to minimize the impact of a porphyria.
Some reference laboratories can measure porphyrins in plasma, bile or other fluids, but this is not usually necessary to make a diagnosis.
In most cases, the answer is no, and the porphyria will remain dormant. It is important, however, to have your latent porphyria identified if you have a family history so that your healthcare provider can tailor any medical treatments to avoid drugs and situations that might trigger signs and symptoms.
No. Porphyrin tests require specialized equipment and technical skills. Some tests may be performed in a local hospital laboratory, while others may need to be sent to a reference laboratory.
Random samples, which are collected at a single time point, are a useful way of screening for a porphyria. If the screening test is positive, a 24-hour urine sample is collected to give a more accurate measurement of how much porphyrin is excreted during one full day.
It may be that her disease has been quiet all this time. It is also possible that the diagnosis made back then was incorrect. Testing for porphyria many years ago was not as accurate and some people may have been diagnosed incorrectly.
Information on the safety of drugs in porphyria is incomplete. Porphyria is a rare disease and many new drugs have been introduced in recent years. Thus, it is often not possible to be sure that a drug is safe until it has been used safely in many patients with porphyria, and this may take years to establish.
Sources Used in Current Review
Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015 Sep 1;8:201-14. Available online at http://www.ncbi.nlm.nih.gov/pubmed/26366103. Accessed May 2016.
Betur S, et al. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites. 2014 Nov 3;4(4):977-1006. Available online http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279155/. Accessed May 2016.
Bissell DM, Wang B. Acute Hepatic Porphyria. J Clin Transl Hepatol. 2015 Mar;3(1):17-26. Available online http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542079/. Accessed May 2016.
Mir, M. and Logue, G. (Updated 2015 October 3). Porphyria Overview. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/1389981-overview. Accessed May 2016.
© 2010-2015 American Porphyria Foundation. About Porphyria, Types of Porphyria. Available online at http://www.porphyriafoundation.com/about-porphyria. Accessed May 2016.
(2015) National Organization for Rare Disorders. Porphyria. Available online at http://rarediseases.org/rare-diseases/porphyria/. Accessed May 2016.
(Updated February 2014) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Porphyria. Available online at http://digestive.niddk.nih.gov/ddiseases/pubs/porphyria/index.aspx. Accessed May 2016.
(Updated 1/27/2015) Chen Y. Porphyrins – urine. MedlinePlus Medical Encyclopedia. Available online at https://www.nlm.nih.gov/medlineplus/ency/article/003614.htm. Accessed May 2016.
Sources Used in Previous Reviews
Schreiber WE. Iron, porphyrin and bilirubin metabolism. In: Clinical Chemistry: Theory, Analysis and Correlation, 4th Ed (LA Kaplan, AJ Pesce, SC Kazmierczak, Eds), CV Mosby, St. Louis, 2003, pp. 657-674.
Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO. Pp325, 670-672.
(2003 March) Porphyria. NIH Publication No. 03-4632, National Digestive Diseases Information Clearinghouse (NDDIC). Available online at http://digestive.niddk.nih.gov/ddiseases/pubs/porphyria/index.htm.
(© 2004) Porphyria Overview. American Porphyria Foundation. Available online at http://www.porphyriafoundation.com/about_por/overview/index.html.
(© 2004) Testing. American Porphyria Foundation. Available online at http://www.porphyriafoundation.com/about_por/testing/index.html.
(© 2004). Three articles [see below]. American Porphyria Foundation, For Physicians. Available online through http://www.porphyriafoundation.com:
AIP, HCP, VP, & ADP, Diagnosis.
Cohen, E. (2003 June 5, Update). Porphyria. MedlinePlus Medical Encyclopedia. Available online: http://www.nlm.nih.gov/medlineplus/ency/article/001208.htm.
(© 1995-2004) Porphyrias, Introduction. The Merck Manual 2nd Home Edition, Section 12. Disorders of Nutrition and Metabolism, Chapter 160. Available online at http://www.merck.com/mrkshared/mmanual_home2/sec12/ch160/ch160a.jsp.
(© 1995-2004). Chapter 14. The Porphyrias. The Merck Manual of Diagnosis and Therapy, Section 2. Endocrine And Metabolic Disorders. Available online at http://www.merck.com/mrkshared/mmanual/section2/chapter14/14a.jsp.
(© 2004). Six articles [see below]. ARUP's Guide to Clinical Laboratory Testing. Available online through http://www.aruplab.com
Aminolevulinic Acid (ALA), Urine.
Porphobilinogen (PBG) Deaminase, Erythrocyte.
Porphobilinogen (PBG), Urine.
Porphyrins, Blood and Serum.
Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 744-745.
Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry, AACC Press, Washington, DC. Pp 439, 440t.
Wu, A. (2006). Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders Elsevier, St. Louis, Missouri. Pp 874-879.
Levin, M. (2007 March 8, Updated). Porphyrins urine. MedlinePlus Medical Encyclopedia. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003614.htm. Accessed on 4/21/08.
Alexander, D. (2007 May 29, Updated). Porphyrins - Blood. MedlinePlus Medical Encyclopedia. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003372.htm. Accessed on 4/21/08.
Frye, R. and DeLoughery, T. (2007 June 26). Pophyria, Acute. emedicine. Available online at http://www.emedicine.com/ped/TOPIC1870.HTM. Accessed on 4/21/08.
(© 2007). About Porphyria and Why laboratory tests are important for diagnosis of porphyrias. American Porphyria Foundation. Available online at http://www.porphyriafoundation.com/about_por/index.html. Accessed on 4/20/08.
Frank, E. and Leiferman, K. (Updated 2011 June). Porphyrias. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/Porphyrias.html?client_ID=LTD. Accessed October 2011.
Mir, M. and Logue, G. (Updated 2009 October 1). Porphyria Overview. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/1389981-overview. Accessed October 2011.
Dugdale, D. (2011 February 28). Porphyrins – blood. Medline Plus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003372.htm. Accessed October 2011.
Dugdale, D. (2011 February 28). Porphyrins – urine. Medline Plus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003614.htm. Accessed October 2011.
Thunell, S. (Updated 2008 August). Overview of Porphyrias, Acute Porphyrias, Cutaneous Porphyrias. Merck Manual for Healthcare Professionals [On-line information]. Available online through http://www.merckmanuals.com. Accessed October 2011.
(© 1995–2011). Unit Code 81052: Porphyrins Profile. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/81052. Accessed October 2011.
(Reviewed 2009 July). Porphyria. Genetics Home Reference [On-line information]. Available online at http://ghr.nlm.nih.gov/condition/porphyria. Accessed October 2011.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 767-768.
Harmening D. Clinical Hematology and Fundamentals of Hemostasis, Fifth Edition, F.A. Davis Company, Philadelphia, 2009, Pp 130-131.
Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL eds (2005). Harrison's Principles of Internal Medicine, 16th Edition, McGraw Hill, Pp 2303-2308.
Schreiber WE. Iron and porphyrin metabolism. In: Clinical Chemistry: Theory, Analysis and Correlation, 5th Ed (LA Kaplan, AJ Pesce, Eds), Mosby, St. Louis, 2009, Pp. 755-770.